J. B. Chemicals & Pharmaceuticals Limited

NSEI:JBCHEPHARM Rapport sur les actions

Capitalisation boursière : ₹271.5b

J. B. Chemicals & Pharmaceuticals Gestion

Gestion contrôle des critères 2/4

Le PDG J. B. Chemicals & Pharmaceuticals est Nikhil Chopra, nommé en Dec2020, a un mandat de 3.92 ans. La rémunération annuelle totale est ₹ 71.34M, composée du salaire de 49.2% et des bonus 50.8%, y compris les actions et options de la société. détient directement 0.026% des actions de la société, d'une valeur de ₹ 69.90M. La durée moyenne de mandat de l'équipe de direction et du conseil d'administration est respectivement 1.8 ans et 4.1 ans.

Informations clés

Nikhil Chopra

Directeur général

₹71.3m

Rémunération totale

Pourcentage du salaire du PDG49.2%
Durée du mandat du directeur général3.9yrs
Propriété du PDG0.03%
Durée moyenne d'occupation des postes de direction1.8yrs
Durée moyenne du mandat des membres du conseil d'administration4.1yrs

Mises à jour récentes de la gestion

Most Shareholders Will Probably Agree With J. B. Chemicals & Pharmaceuticals Limited's (NSE:JBCHEPHARM) CEO Compensation

Aug 15
Most Shareholders Will Probably Agree With J. B. Chemicals & Pharmaceuticals Limited's (NSE:JBCHEPHARM) CEO Compensation

Recent updates

We Think J. B. Chemicals & Pharmaceuticals (NSE:JBCHEPHARM) Can Stay On Top Of Its Debt

Nov 27
We Think J. B. Chemicals & Pharmaceuticals (NSE:JBCHEPHARM) Can Stay On Top Of Its Debt

J. B. Chemicals & Pharmaceuticals Limited (NSE:JBCHEPHARM) Just Released Its Second-Quarter Results And Analysts Are Updating Their Estimates

Nov 09
J. B. Chemicals & Pharmaceuticals Limited (NSE:JBCHEPHARM) Just Released Its Second-Quarter Results And Analysts Are Updating Their Estimates

J. B. Chemicals & Pharmaceuticals Limited's (NSE:JBCHEPHARM) Business Is Yet to Catch Up With Its Share Price

Sep 24
J. B. Chemicals & Pharmaceuticals Limited's (NSE:JBCHEPHARM) Business Is Yet to Catch Up With Its Share Price

Most Shareholders Will Probably Agree With J. B. Chemicals & Pharmaceuticals Limited's (NSE:JBCHEPHARM) CEO Compensation

Aug 15
Most Shareholders Will Probably Agree With J. B. Chemicals & Pharmaceuticals Limited's (NSE:JBCHEPHARM) CEO Compensation

J. B. Chemicals & Pharmaceuticals Limited Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next

Aug 11
J. B. Chemicals & Pharmaceuticals Limited Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next

These 4 Measures Indicate That J. B. Chemicals & Pharmaceuticals (NSE:JBCHEPHARM) Is Using Debt Reasonably Well

Jun 28
These 4 Measures Indicate That J. B. Chemicals & Pharmaceuticals (NSE:JBCHEPHARM) Is Using Debt Reasonably Well

J. B. Chemicals & Pharmaceuticals Limited (NSE:JBCHEPHARM) Not Flying Under The Radar

Apr 19
J. B. Chemicals & Pharmaceuticals Limited (NSE:JBCHEPHARM) Not Flying Under The Radar

J. B. Chemicals & Pharmaceuticals Limited Just Missed Earnings - But Analysts Have Updated Their Models

Feb 09
J. B. Chemicals & Pharmaceuticals Limited Just Missed Earnings - But Analysts Have Updated Their Models

J. B. Chemicals & Pharmaceuticals Limited (NSE:JBCHEPHARM) Not Flying Under The Radar

Dec 22
J. B. Chemicals & Pharmaceuticals Limited (NSE:JBCHEPHARM) Not Flying Under The Radar

We Think J. B. Chemicals & Pharmaceuticals (NSE:JBCHEPHARM) Can Stay On Top Of Its Debt

Nov 29
We Think J. B. Chemicals & Pharmaceuticals (NSE:JBCHEPHARM) Can Stay On Top Of Its Debt

J. B. Chemicals & Pharmaceuticals' (NSE:JBCHEPHARM) Dividend Will Be Increased To ₹9.25

Aug 03
J. B. Chemicals & Pharmaceuticals' (NSE:JBCHEPHARM) Dividend Will Be Increased To ₹9.25

J. B. Chemicals & Pharmaceuticals (NSE:JBCHEPHARM) Is Due To Pay A Dividend Of ₹8.50

Feb 11
J. B. Chemicals & Pharmaceuticals (NSE:JBCHEPHARM) Is Due To Pay A Dividend Of ₹8.50

Is J. B. Chemicals & Pharmaceuticals (NSE:JBCHEPHARM) Using Too Much Debt?

Dec 03
Is J. B. Chemicals & Pharmaceuticals (NSE:JBCHEPHARM) Using Too Much Debt?

A Look At The Intrinsic Value Of J. B. Chemicals & Pharmaceuticals Limited (NSE:JBCHEPHARM)

Sep 21
A Look At The Intrinsic Value Of J. B. Chemicals & Pharmaceuticals Limited (NSE:JBCHEPHARM)

J. B. Chemicals & Pharmaceuticals (NSE:JBCHEPHARM) Seems To Use Debt Quite Sensibly

Aug 03
J. B. Chemicals & Pharmaceuticals (NSE:JBCHEPHARM) Seems To Use Debt Quite Sensibly

Estimating The Fair Value Of J. B. Chemicals & Pharmaceuticals Limited (NSE:JBCHEPHARM)

Jun 15
Estimating The Fair Value Of J. B. Chemicals & Pharmaceuticals Limited (NSE:JBCHEPHARM)

Does J. B. Chemicals & Pharmaceuticals (NSE:JBCHEPHARM) Have A Healthy Balance Sheet?

Mar 29
Does J. B. Chemicals & Pharmaceuticals (NSE:JBCHEPHARM) Have A Healthy Balance Sheet?

J. B. Chemicals & Pharmaceuticals (NSE:JBCHEPHARM) Has Re-Affirmed Its Dividend Of ₹8.50

Feb 16
J. B. Chemicals & Pharmaceuticals (NSE:JBCHEPHARM) Has Re-Affirmed Its Dividend Of ₹8.50

Analyse de la rémunération des PDG

Comment la rémunération de Nikhil Chopra a-t-elle évolué par rapport aux bénéfices de J. B. Chemicals & Pharmaceuticals?
DateRémunération totaleSalaireBénéfices de l'entreprise
Sep 30 2024n/an/a

₹6b

Jun 30 2024n/an/a

₹6b

Mar 31 2024₹71m₹35m

₹6b

Dec 31 2023n/an/a

₹5b

Sep 30 2023n/an/a

₹5b

Jun 30 2023n/an/a

₹4b

Mar 31 2023₹65m₹37m

₹4b

Dec 31 2022n/an/a

₹4b

Sep 30 2022n/an/a

₹4b

Jun 30 2022n/an/a

₹4b

Mar 31 2022₹59m₹18m

₹4b

Dec 31 2021n/an/a

₹4b

Sep 30 2021n/an/a

₹5b

Jun 30 2021n/an/a

₹4b

Mar 31 2021₹32m₹7m

₹4b

Rémunération vs marché: La rémunération totale de Nikhil ($USD 846.14K ) est supérieure à la moyenne des entreprises de taille similaire sur le marché Indian ($USD 610.84K ).

Rémunération et revenus: La rémunération de Nikhil a été cohérente avec les performances de l'entreprise au cours de l'année écoulée.


PDG

Nikhil Chopra (51 yo)

3.9yrs

Titularisation

₹71,338,000

Compensation

Mr. Nikhil Ashokkumar Chopra serves as Chief Executive Officer and Whole-Time Director at J. B. Chemicals & Pharmaceuticals Limited since December 23, 2020 and has been its Director since May 10, 2020. He...


Équipe de direction

NomPositionTitularisationCompensationPropriété
Nikhil Chopra
CEO & Whole-Time Director3.9yrs₹71.34m0.026%
₹ 69.9m
Suresh Amin
Assistant Vice President – Human Resourceno data₹10.48m0.0025%
₹ 6.7m
Narayan Saraf
Chief Financial Officerless than a year₹12.74mpas de données
Kunal Khanna
President of Operationsno data₹28.44mpas de données
Bhagwat Deora
Vice President of Finance & Accountsno data₹9.48mpas de données
Suresh Bhise
Vice President of Information & Technology9.8yrs₹10.70mpas de données
Sridhar Bharadwaj
Vice President of HR & Administration8.2yrs₹13.80m0.00084%
₹ 2.3m
Himanshu Ranvah
Vice President of Legal1.8yrs₹11.49mpas de données
Pradeep Singh
President of Global Businessno data₹42.09m0.012%
₹ 31.5m
Parmeshwar Bang
Executive Vice President of Operations of Daman1.3yrs₹17.24m0.0048%
₹ 13.1m
Bhushan Sachdev
Executive Vice President of Supply Chain Operationsno data₹19.54m0.0084%
₹ 22.7m
Jason D'Souza
Executive Vice Presidentless than a year₹18.12m0.0032%
₹ 8.7m

1.8yrs

Durée moyenne de l'emploi

51yo

Âge moyen

Gestion expérimentée: L'équipe de direction de JBCHEPHARM n'est pas considérée comme expérimentée (ancienneté moyenne 1.8 ans), ce qui suggère une nouvelle équipe.


Membres du conseil d'administration

NomPositionTitularisationCompensationPropriété
Nikhil Chopra
CEO & Whole-Time Director4.1yrs₹71.34m0.026%
₹ 69.9m
Shadrack Mapetla
Chairman of Biotech Laboratories (Pty ) Ltdno datapas de donnéespas de données
Arun Duggal
Non-Executive Independent Chairmanless than a yearpas de donnéespas de données
Padmini Kaicker
Non-Executive & Independent Director4.3yrs₹7.50mpas de données
Prashant Kumar
Non-Executive Director4.3yrspas de donnéespas de données
Akshay Tanna
Non-Executive & Non-Independent Directorless than a yearpas de donnéespas de données
Gaurav Trehan
Non-Executive Director3.8yrspas de donnéespas de données
Sumit Bose
Non-Executive & Independent Director4.3yrs₹7.50mpas de données

4.1yrs

Durée moyenne de l'emploi

64.5yo

Âge moyen

Conseil d'administration expérimenté: Les membres du conseil d'administration de JBCHEPHARM sont considérés comme expérimentés (ancienneté moyenne 4.1 ans).